Eintrag weiter verarbeiten
Consequences and management of iron overload in sickle cell disease
Gespeichert in:
| Zeitschriftentitel: | Hematology |
|---|---|
| Personen und Körperschaften: | , |
| In: | Hematology, 2013, 2013, 1, S. 447-456 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Hematology
|
| Schlagwörter: |
| author_facet |
Porter, John Garbowski, Maciej Porter, John Garbowski, Maciej |
|---|---|
| author |
Porter, John Garbowski, Maciej |
| spellingShingle |
Porter, John Garbowski, Maciej Hematology Consequences and management of iron overload in sickle cell disease Hematology |
| author_sort |
porter, john |
| spelling |
Porter, John Garbowski, Maciej 1520-4391 1520-4383 American Society of Hematology Hematology http://dx.doi.org/10.1182/asheducation-2013.1.447 <jats:title>Abstract</jats:title> <jats:p>The aims of this review are to highlight the mechanisms and consequences of iron distribution that are most relevant to transfused sickle cell disease (SCD) patients and to address the particular challenges in the monitoring and treatment of iron overload. In contrast to many inherited anemias, in SCD, iron overload does not occur without blood transfusion. The rate of iron loading in SCD depends on the blood transfusion regime: with simple hypertransfusion regimes, rates approximate to thalassemia major, but iron loading can be minimal with automated erythrocyte apheresis. The consequences of transfusional iron overload largely reflect the distribution of storage iron. In SCD, a lower proportion of transfused iron distributes extrahepatically and occurs later than in thalassemia major, so complications of iron overload to the heart and endocrine system are less common. We discuss the mechanisms by which these differences may be mediated. Treatment with iron chelation and monitoring of transfusional iron overload in SCD aim principally at controlling liver iron, thereby reducing the risk of cirrhosis and hepatocellular carcinoma. Monitoring of liver iron concentration pretreatment and in response to chelation can be estimated using serum ferritin, but noninvasive measurement of liver iron concentration using validated and widely available MRI techniques reduces the risk of under- or overtreatment. The optimal use of chelation regimes to achieve these goals is described.</jats:p> Consequences and management of iron overload in sickle cell disease Hematology |
| doi_str_mv |
10.1182/asheducation-2013.1.447 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9hc2hlZHVjYXRpb24tMjAxMy4xLjQ0Nw |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9hc2hlZHVjYXRpb24tMjAxMy4xLjQ0Nw |
| institution |
DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Zi4 DE-Gla1 DE-15 DE-Pl11 DE-Rs1 DE-14 DE-105 DE-Ch1 DE-L229 DE-D275 |
| imprint |
American Society of Hematology, 2013 |
| imprint_str_mv |
American Society of Hematology, 2013 |
| issn |
1520-4391 1520-4383 |
| issn_str_mv |
1520-4391 1520-4383 |
| language |
English |
| mega_collection |
American Society of Hematology (CrossRef) |
| match_str |
porter2013consequencesandmanagementofironoverloadinsicklecelldisease |
| publishDateSort |
2013 |
| publisher |
American Society of Hematology |
| recordtype |
ai |
| record_format |
ai |
| series |
Hematology |
| source_id |
49 |
| title |
Consequences and management of iron overload in sickle cell disease |
| title_unstemmed |
Consequences and management of iron overload in sickle cell disease |
| title_full |
Consequences and management of iron overload in sickle cell disease |
| title_fullStr |
Consequences and management of iron overload in sickle cell disease |
| title_full_unstemmed |
Consequences and management of iron overload in sickle cell disease |
| title_short |
Consequences and management of iron overload in sickle cell disease |
| title_sort |
consequences and management of iron overload in sickle cell disease |
| topic |
Hematology |
| url |
http://dx.doi.org/10.1182/asheducation-2013.1.447 |
| publishDate |
2013 |
| physical |
447-456 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>The aims of this review are to highlight the mechanisms and consequences of iron distribution that are most relevant to transfused sickle cell disease (SCD) patients and to address the particular challenges in the monitoring and treatment of iron overload. In contrast to many inherited anemias, in SCD, iron overload does not occur without blood transfusion. The rate of iron loading in SCD depends on the blood transfusion regime: with simple hypertransfusion regimes, rates approximate to thalassemia major, but iron loading can be minimal with automated erythrocyte apheresis. The consequences of transfusional iron overload largely reflect the distribution of storage iron. In SCD, a lower proportion of transfused iron distributes extrahepatically and occurs later than in thalassemia major, so complications of iron overload to the heart and endocrine system are less common. We discuss the mechanisms by which these differences may be mediated. Treatment with iron chelation and monitoring of transfusional iron overload in SCD aim principally at controlling liver iron, thereby reducing the risk of cirrhosis and hepatocellular carcinoma. Monitoring of liver iron concentration pretreatment and in response to chelation can be estimated using serum ferritin, but noninvasive measurement of liver iron concentration using validated and widely available MRI techniques reduces the risk of under- or overtreatment. The optimal use of chelation regimes to achieve these goals is described.</jats:p> |
| container_issue |
1 |
| container_start_page |
447 |
| container_title |
Hematology |
| container_volume |
2013 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792346414273003520 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:39:01.382Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Consequences+and+management+of+iron+overload+in+sickle+cell+disease&rft.date=2013-12-06&genre=article&issn=1520-4383&volume=2013&issue=1&spage=447&epage=456&pages=447-456&jtitle=Hematology&atitle=Consequences+and+management+of+iron+overload+in+sickle+cell+disease&aulast=Garbowski&aufirst=Maciej&rft_id=info%3Adoi%2F10.1182%2Fasheducation-2013.1.447&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792346414273003520 |
| author | Porter, John, Garbowski, Maciej |
| author_facet | Porter, John, Garbowski, Maciej, Porter, John, Garbowski, Maciej |
| author_sort | porter, john |
| container_issue | 1 |
| container_start_page | 447 |
| container_title | Hematology |
| container_volume | 2013 |
| description | <jats:title>Abstract</jats:title> <jats:p>The aims of this review are to highlight the mechanisms and consequences of iron distribution that are most relevant to transfused sickle cell disease (SCD) patients and to address the particular challenges in the monitoring and treatment of iron overload. In contrast to many inherited anemias, in SCD, iron overload does not occur without blood transfusion. The rate of iron loading in SCD depends on the blood transfusion regime: with simple hypertransfusion regimes, rates approximate to thalassemia major, but iron loading can be minimal with automated erythrocyte apheresis. The consequences of transfusional iron overload largely reflect the distribution of storage iron. In SCD, a lower proportion of transfused iron distributes extrahepatically and occurs later than in thalassemia major, so complications of iron overload to the heart and endocrine system are less common. We discuss the mechanisms by which these differences may be mediated. Treatment with iron chelation and monitoring of transfusional iron overload in SCD aim principally at controlling liver iron, thereby reducing the risk of cirrhosis and hepatocellular carcinoma. Monitoring of liver iron concentration pretreatment and in response to chelation can be estimated using serum ferritin, but noninvasive measurement of liver iron concentration using validated and widely available MRI techniques reduces the risk of under- or overtreatment. The optimal use of chelation regimes to achieve these goals is described.</jats:p> |
| doi_str_mv | 10.1182/asheducation-2013.1.447 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9hc2hlZHVjYXRpb24tMjAxMy4xLjQ0Nw |
| imprint | American Society of Hematology, 2013 |
| imprint_str_mv | American Society of Hematology, 2013 |
| institution | DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-105, DE-Ch1, DE-L229, DE-D275 |
| issn | 1520-4391, 1520-4383 |
| issn_str_mv | 1520-4391, 1520-4383 |
| language | English |
| last_indexed | 2024-03-01T17:39:01.382Z |
| match_str | porter2013consequencesandmanagementofironoverloadinsicklecelldisease |
| mega_collection | American Society of Hematology (CrossRef) |
| physical | 447-456 |
| publishDate | 2013 |
| publishDateSort | 2013 |
| publisher | American Society of Hematology |
| record_format | ai |
| recordtype | ai |
| series | Hematology |
| source_id | 49 |
| spelling | Porter, John Garbowski, Maciej 1520-4391 1520-4383 American Society of Hematology Hematology http://dx.doi.org/10.1182/asheducation-2013.1.447 <jats:title>Abstract</jats:title> <jats:p>The aims of this review are to highlight the mechanisms and consequences of iron distribution that are most relevant to transfused sickle cell disease (SCD) patients and to address the particular challenges in the monitoring and treatment of iron overload. In contrast to many inherited anemias, in SCD, iron overload does not occur without blood transfusion. The rate of iron loading in SCD depends on the blood transfusion regime: with simple hypertransfusion regimes, rates approximate to thalassemia major, but iron loading can be minimal with automated erythrocyte apheresis. The consequences of transfusional iron overload largely reflect the distribution of storage iron. In SCD, a lower proportion of transfused iron distributes extrahepatically and occurs later than in thalassemia major, so complications of iron overload to the heart and endocrine system are less common. We discuss the mechanisms by which these differences may be mediated. Treatment with iron chelation and monitoring of transfusional iron overload in SCD aim principally at controlling liver iron, thereby reducing the risk of cirrhosis and hepatocellular carcinoma. Monitoring of liver iron concentration pretreatment and in response to chelation can be estimated using serum ferritin, but noninvasive measurement of liver iron concentration using validated and widely available MRI techniques reduces the risk of under- or overtreatment. The optimal use of chelation regimes to achieve these goals is described.</jats:p> Consequences and management of iron overload in sickle cell disease Hematology |
| spellingShingle | Porter, John, Garbowski, Maciej, Hematology, Consequences and management of iron overload in sickle cell disease, Hematology |
| title | Consequences and management of iron overload in sickle cell disease |
| title_full | Consequences and management of iron overload in sickle cell disease |
| title_fullStr | Consequences and management of iron overload in sickle cell disease |
| title_full_unstemmed | Consequences and management of iron overload in sickle cell disease |
| title_short | Consequences and management of iron overload in sickle cell disease |
| title_sort | consequences and management of iron overload in sickle cell disease |
| title_unstemmed | Consequences and management of iron overload in sickle cell disease |
| topic | Hematology |
| url | http://dx.doi.org/10.1182/asheducation-2013.1.447 |